FIRST AMENDMENT TO DEVELOPMENT COLLABORATION AND EXCLUSIVE LICENSE AGREEMENTDevelopment Collaboration and Exclusive License Agreement • November 12th, 2019 • Molecular Templates, Inc. • Pharmaceutical preparations
This First Amendment to Development Collaboration and Exclusive License Agreement (this “Amendment”) is made and entered into as of July 18, 2019 (the “Amendment Effective Date”) by and between Molecular Templates, Inc., a Delaware corporation, having its principal place of business at 9301 Amberglen Boulevard, Suite 100, Austin, TX 78729 (“MTEM”), and Millennium Pharmaceuticals, Inc., a Delaware corporation and a wholly-owned subsidiary of Takeda Pharmaceutical Company Limited, having its principal place of business at 40 Landsdowne Street, Cambridge, MA 02139 (“Takeda”). MTEM and Takeda may be referred to herein collectively as the “Parties” and individually as a “Party.”
DEVELOPMENT COLLABORATION AND exclusive LICENSE AGREEMENTDevelopment Collaboration and Exclusive License Agreement • November 13th, 2018 • Molecular Templates, Inc. • Pharmaceutical preparations • Massachusetts
This Development Collaboration and Exclusive License Agreement (this “Agreement”) is entered into as of September 18, 2018 (the “Effective Date”) by and between MOLECULAR TEMPLATES, INC., a Delaware corporation, having its principal place of business at 9301 Amberglen Boulevard, Suite 100, Austin, TX 78729 (“MTEM”) and MILLENNIUM PHARMACEUTICALS, INC., a Delaware corporation, a wholly-owned subsidiary of Takeda Pharmaceutical Company Limited, having its principal place of business at 40 Landsdowne Street, Cambridge, MA 02139 (“Takeda”). MTEM and Takeda may sometimes individually be referred to hereafter as a “Party” or collectively as the “Parties.”
